Display Settings:

Format

Send to:

Choose Destination

    Nat Med. 2008 May;14(5):536-41. Epub 2008 Apr 20.

    Mast cell activators: a new class of highly effective vaccine adjuvants.

    McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, Brooking-Dixon R, Staats HF, Abraham SN.

    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.

    Comment in:

    Mast cells (MCs) have recently received recognition as prominent effectors in the regulation of immune cell migration to draining lymph nodes and lymphocyte activation. However, their role in the development of humoral immune responses is not clear. Here, we demonstrate that subcutaneous or nasal administration of small-molecule MC activators with vaccine antigens evokes large increases in antigen-specific serum immunoglobulin G (IgG) responses. These responses were MC dependent and correlated with increased dendritic cell and lymphocyte recruitment to draining lymph nodes. Nasal instillation of these formulations also evoked antigen-specific secretory IgA and provided protection against anthrax lethal toxin challenge in vitro and against vaccinia virus infection in vivo. Collectively, these results define the MC as an integral sensory arm of the adaptive immune system. Moreover, they highlight MC activators as a new class of vaccine adjuvants, capable of inducing protective antigen-specific immune responses through needle-free routes of administration.

    PMID: 18425129 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Anthrax Vaccine (Biothrax®)

      Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria calledBacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides. In its most common...